透皮东莨菪碱作为全关节置换术患者多模式疼痛管理的辅助手段
该回顾性队列研究纳入2014至2017年间连续接受全关节置换术的患者,比较加用东莨菪碱贴片前(对照组)与加用后(研究组)的患者,发现研究组术后恶心呕吐发生率显著降低(14.4% vs 29.3%,P < .0001),术后第0至2天疼痛评分更低,术后第0至3天行走距离更远,术后第1、2天吗啡当量用量更少,但术后第0天研究组吗啡当量用量更多。作者认为这些数据支持将透皮东莨菪碱作为全关节置换术患者多模式围手术期疼痛方案的一部分。
要点
- 研究组术后恶心呕吐发生率为14.4%,显著低于对照组的29.3%(P < .0001)。
- 研究组术后第0至2天视觉模拟评分疼痛评分更低(P < .01),术后第0至3天行走距离更远(P < .001)。
- 研究组术后第1、2天吗啡当量用量更少(P < .001),但术后第0天吗啡当量用量更多。
核心结论
- 使用东莨菪碱贴片与全关节置换术后恶心呕吐显著降低及功能结局改善相关。
- 作者认为这些数据支持将透皮东莨菪碱作为全关节置换术患者多模式围手术期疼痛方案的一部分。
研究设计与样本
- 回顾性队列研究,回顾了2014年至2017年间连续接受全关节置换术的1580例患者的病历。
- 比较加用东莨菪碱贴片前(对照组)与加用后(研究组)的患者,除非有禁忌证,患者在等候区接受东莨菪碱贴片。
- 共495例患者被排除。
主要发现
- 研究组术后恶心呕吐发生率为14.4%,对照组为29.3%,研究组显著低于对照组(P < .0001)。
- 研究组术后第0至2天视觉模拟评分疼痛评分低于对照组(P < .01)。
- 研究组术后第0至3天行走距离大于对照组(P < .001)。
- 研究组术后第1、2天吗啡当量用量少于对照组(P < .001)。
- 研究组术后第0天吗啡当量用量多于对照组。
临床怎么用
- 作者认为这些数据支持将透皮东莨菪碱作为全关节置换术患者多模式围手术期疼痛方案的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) after surgery degrades patient experience, tolerance of pain medication, rehabilitation progress, and functional outcomes. Given the importance of early rehabilitation following total joint arthroplasty (TJA), we asked whether transdermal scopolamine is effective in reducing rates of PONV and improving functional outcomes following TJA. METHODS: We retrospectively reviewed the charts of 1580 consecutive patients who underwent TJA between 2014 and 2017 and compared patients before the addition of the scopolamine patch (control group) to those after the addition (study group). Patients were given the scopolamine patch in the holding area unless contraindicated. A total of 495 patients were excluded. Charts were reviewed for PONV, demographic information, surgical time, length of stay, distance walked with physical therapy, and Visual Analog Scale pain scores. Student t-test was used to compare continuous data and chi-square was used for categorical variables. RESULTS: The incidence of PONV was significantly lower in the study group compared to the control group (14.4% vs 29.3%, P < .0001). Patients who were given scopolamine had lower Visual Analog Scale pain scores on postoperative days (POD) 0 through 2 (P < .01), were able to walk further distances on POD 0 through 3 (P < .001), and received fewer morphine equivalents on POD 1 and 2 (P < .001). Greater morphine equivalents were received by the study group on POD 0. CONCLUSION: Use of a scopolamine patch was associated with significant reduction in PONV and improvement in functional outcomes following TJA. These data support the use of transdermal scopolamine as part of a multimodal, perioperative pain protocol in patients undergoing TJA.
引用
- Berg AR, Lakra A, Jennings EL, et al. Transdermal Scopolamine as an Adjunct to Multimodal Pain Management in Patients Undergoing Total Joint Arthroplasty. J Arthroplasty. 2019. PMID: 30992239. doi:10.1016/j.arth.2019.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。